Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis

Use of Pranoprofen After Strabismus Surgery in Children

Objectives: The aim of our study is to evaluate the efficacy of pranoprofen 0.1% in preventing the occurrence of postoperative complications, including postoperative ocular inflammation after strabismus surgery in children. Methods: 90 children operated on for strabismus in the Department of Paediatric Ophthalmology and Strabismus of the Medical University of Bialystok between 2022 and 2023 were included in the study. The patients were aged from 2 to 17 years old. Patients were divided into three groups of 30 patients according to the method of topical postoperative treatment (group I: tobramycin, pranoprofen, dexpanthenol; group II: tobramycin, dexamethasone, dexpanthenol; group III: tobramycin, pranoprofen, dexamethasone, dexpanthenol). Patients were followed up the day after surgery, on postoperative day 14 and then 3 months after surgery. Results: No child showed signs of postoperative infection. There was one case of allergic reaction each in groups I and III. Most complications were present in group II (six cases: there were allergic reactions that occurred in three patients. Two patients experienced a complication in the form of delle, while one patient developed a granuloma), which was a statistically significant difference compared to groups I and III (p = 0.032). Conclusions: Pranoprofen used postoperatively is as effective as a glucocorticosteroid, and from our observations, carries fewer complications in cases requiring prolonged use of the anti-inflammatory treatment. Systematic postoperative follow-up is essential for the diagnosis and possible management of postsurgical complications.

Clinical Efficacy of Tobramycin Dexamethasone+Pranoprofen Eye Drops on Endophthalmitis in Cataract Patients Complicated with Diabetes Mellitus after Intraocular Lens Implantation

BACKGROUND

There is little research on the anti-inflammatory efficacy and safety of tobramycin dexamethasone+pranoprofen eye drops in treating endophthalmitis.

AIM

To appraise the efficacy and safety of tobramycin dexamethasone+propranolofen eye drops in the treatment of endophthalmitis.

METHODS

The degree of corneal edema, foveal thickness, score of anterior chamber (AC) flares, best corrected visual acuity (BCVA), fasting blood glucose, inflammatory indexes of serum and aqueous humor, and adverse reactions were observed every week.

RESULTS

After the intervention with tobramycin dexamethasone+pranoprofen eye drops, corneal edema and foveal thickness reduced, BCVA improved, and the inflammatory markers in serum and aqueous humor decreased. Moreover, the incidence of adverse reactions in the tobramycin dexamethasone+pranoprofen group was lower than that in the control group and the fluorometholone group (P < 0.05).

CONCLUSION

Tobramycin dexamethasone+pranoprofen eye drops can inhibit inflammation better, recover vision faster, and make the incidence of adverse reactions lower in treating cataract patients complicated with DM developing endophthalmitis induced.

Synthesis and Biological Activity of Chromeno[3,2-c]Pyridines

The review summarizes all synthetic methodologies for the preparation of chromeno[3,2-c]pyridines and chromeno[3,2-c]quinolines. The proposed approaches are systemized based on ways for the construction of the heterocyclic system. The presence of these compounds in nature and their bioactivity are also discussed. Natural products with an annelated chromeno[3,2-c]pyridine fragment are well-known and a number of alkaloids derived from this system as a key core have been recently isolated. These compounds demonstrate antimicrobial, antivirus, and cytotoxic activities, making chromeno[3,2-c]pyridine structural motifs promising for medicinal chemistry.

Executive summary: Japanese guidelines for allergic conjunctival diseases 2021

Allergic conjunctival disease (ACD) is an inflammatory disease of the conjunctiva that is mainly caused by type I hypersensitivity response to allergens and accompanied by subjective symptoms and other findings induced by antigens. ACD is classified as allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. This article summarizes the third edition of the Japanese guidelines for allergic conjunctival diseases published in 2021 and outlines the diagnosis, pathogenesis, and treatment of ACD. Since the introduction of immunosuppressive eye drops, the treatment strategies for severe ACDs have significantly changed. To clarify the recommended standard treatment protocols for ACD, the advantages and disadvantages of these treatments were assessed using clinical questions, with a focus on the use of steroids and immunosuppressive drugs. This knowledge will assist healthcare providers and patients in taking an active role in medical decision making.

Efficacy and safety of hyaluronic acid fillers for lip augmentation in a Chinese population

BACKGROUND

Hyaluronic acid (HA) is an effective dermal filler for facial rejuvenation. This study aimed to observe the clinical efficacy of HA injection for lip augmentation in Chinese patients.

METHODS

From May 2019 to April 2020, 70 patients with lip fullness scale (LPS) ≤3 underwent local HA injection using the "three-point" injection technique. All patients were followed up to observe the clinical efficacy, LPS, adverse events, and complications.

RESULTS

All 70 patients were followed up for 12 months. Statistically significant improvements were observed in the height of lips within 6-9 months post-treatment (p < 0.05). The LFS improved significantly at follow-up compared with baseline (p < 0.05). Local redness occurred in two patients, and serious swelling occurred in three patients. These adverse events were generally tolerated and disappeared gradually within 1 week. No other serious adverse events and complications were reported in the remaining patients.

CONCLUSIONS

Hyaluronic acid injection can be used for lip augmentation in the Chinese population. The "three-point" technique is simple, safe, and effective and does not cause serious complications.

Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

Purpose: To evaluate the effect of a topical nonsteroidal anti-inflammatory drug (0.1% pranoprofen) on the expression of VEGF and Cox-2 in primary pterygium.

Methods: This was a prospective, randomized study. Between January 2019 and April 2020, 120 patients diagnosed with primary pterygium were enrolled and randomly divided into three groups before operation: 1) 40 patients in group 1 received topical pranoprofen 0.1% four times daily for 4 weeks, 2) 40 patients in group 2 received topical fluorometholone 0.1% four times daily for 4 weeks, and 3) patients in group 3 did not receive treatment. For each group, the age, sex, eye type, best-corrected visual acuity (BCVA), intraocular pressure (IOP), duration of onset, combined systemic diseases, and the results regarding vascular endothelial growth factor (VEGF) and cyclo-oxygen-ase-2 (COX-2) in postoperative pterygial tissues were evaluated in detail.

Results: There were no significant differences regarding age, sex, eye type, combined systemic diseases, duration of onset, IOP, and BCVA within the three groups (p > 0.05). The reduction of VEGF and CoX-2 expression of pterygial vascular endothelial cells in group 1 were statistically significant compared to group 2 and group 3 (p < 0.05). There were significant correlations between COX-2 and VEGF expression of pterygial tissues within the three groups (p < 0.05).

Conclusion: The present findings suggested that the topical pranoprofen 0.1% could reduce the expression of VEGF and COX-2 in primary pterygium. We confirmed that treatment with pranoprofen offers advantages in early intervention and has therapeutic potential in reducing the postoperative recurrence of primary pterygium patients.

Clinical Trial registration: The study was registered with the Chinese Clinical Trial Registry. (http://www.chictr.org.cn/index.aspx, Registration Number: ChiCTR2100047726).

Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study

Objective Oxidative stress appears to be a key factor in the pathogenesis of allergic diseases and a potential therapeutic target in allergy treatment. Allergic diseases are reportedly associated with reduced plasma levels of ascorbate, which is a key physiological antioxidant. Ascorbate prevents excessive inflammation without reducing the defensive capacity of the immune system. Methods An interim analysis of a multicenter, prospective, observational study was conducted to investigate the change in disease-specific and nonspecific symptoms (fatigue, sleep disorders, depression, and lack of mental concentration) during adjuvant treatment with intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany) in 71 patients with allergy-related respiratory or cutaneous indications. Results Between the start and end of treatment, the mean sum score of three disease-specific symptoms decreased significantly by 4.71 points and that of four nonspecific symptoms decreased significantly by 4.84 points. More than 50% of patients took no other allergy-related medication besides vitamin C. Conclusions Our observations suggest that treatment with intravenous high-dose vitamin C reduces allergy-related symptoms. Our observations form a basis for planning a randomized controlled clinical trial to obtain more definitive evidence of the clinical relevance of our findings. We also obtained evidence of ascorbate deficiency in allergy-related diseases.

TRIAL REGISTRATION

Clinical Trials NCT02422901.

Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model

PURPOSE

To evaluate the efficacy and safety of a sustained-release dexamethasone intracanalicular insert (Dextenza™) in a model of allergic conjunctivitis.

METHODS

This was a randomized, double-masked, vehicle-controlled, Phase 2 study. Subjects had to have a positive conjunctival allergen challenge (CAC) reaction to allergen (bilateral +2 itching and redness on 5-point, 0-4 scales) at Visit 1, and for 2 of 3 time points on subsequent visits. Subjects who met entry criteria were randomized to receive Dextenza or PV (vehicle insert). Challenges occurred over 42 days, with efficacy assessed at 14 (primary endpoint visit), 28, and 40 days postinsertion. Outcome measures included the evaluation of ocular itching, redness, tearing, chemosis, eyelid swelling, rhinorrhea, and congestion.

RESULTS

Twenty-eight subjects completed the study in the Dextenza group and 31 in the vehicle group. At 14 days postinsertion, Dextenza was statistically superior to PV, with least square mean differences for ocular itching of -0.76, -0.97, and -0.87 at 3, 5, and 7 min post-CAC, and for conjunctival redness of -0.46, -0.66, and -0.68 at 7, 15, and 20 min post-CAC. Clinical significance, defined as a 1-U decrease from PV, was not met for primary efficacy. Secondary endpoints, including number of subjects reporting itching and conjunctival redness, indicated superior performance of Dextenza compared with vehicle. Eleven Dextenza-treated (35.5%) and 10 vehicle-treated (30.3%) subjects each experienced a single adverse event.

CONCLUSION

This Phase 2 study demonstrated preliminary efficacy and safety data of Dextenza for treatment of allergic conjunctivitis.

Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease

PURPOSE

To evaluate the efficacy of bromfenac sodium ophthalmic solution (BF) in patients with dry eye disease (DED) inadequately controlled by monotherapy with artificial tears (ATs).

DESIGN

An investigator-oriented trial with a single-arm, nonrandomized, open-label design.

METHODS

Twenty-six patients, who showed no symptomatic improvement of DED after 1 month of AT treatment, were enrolled. Bromfenac sodium ophthalmic solution was administered adjunctively with AT for 1 month. The BF treatment was then discontinued, and AT treatment alone was continued for 3 months. The signs and symptoms were evaluated at the beginning of BF treatment (Pre), at the end of the combined BF and AT treatment (BF1M), and at 1 and 3 months after discontinuation of BF treatment (Po1M and Po3M, respectively).

RESULTS

The dryness scores at BF1M were significantly improved compared with Pre (P < 0.001) and significantly superior to Po3M (P < 0.001). No significant changes in the Schirmer scores were observed throughout the treatment period. The tear film breakup time was significantly improved at BF1M (4.4 ± 2.3 seconds) compared with Pre (2.8 ± 1.8 seconds; P < 0.001). Superficial punctate keratopathy showed significant improvements in the total score of area and density at BF1M compared with Pre (P < 0.001). However, these parameters had significantly worsened at Po3M compared with BF1M. No adverse events were observed.

CONCLUSIONS

Bromfenac sodium ophthalmic solution has improved the dryness of the eye and signs of DED through its anti-inflammatory effects. Nonsteroidal anti-inflammatory drugs were suitable as anti-inflammatory ophthalmic solutions for patients with DED.

Emerging drugs for allergic conjunctivitis

INTRODUCTION

Allergic conjunctivitis (AC) is a very common disease, especially in association with allergic rhinitis but may also occur in isolated presentation. The treatment of AC has long been based on antihistamines, cromones and topical corticosteroids, but none of these drugs completely abolishes the clinical expression of AC.

AREAS COVERED

The development of new drugs for AC is analyzed highlighting the recent insights into the pathophysiological mechanisms of the disease. The major aim of development of drugs for AC is to have agents able to prevent the inflammatory effects of the interaction between the allergen and the specific IgE antibodies on mast cell surface. This may be obtained by blocking the effects of histamine (the main mediator of early allergic response) by H1-receptor antagonists, inhibiting the release of soluble factors able to recruit inflammatory cells (that sustain prolonged inflammation) by mast-cell stabilizers, inhibiting the effects of single mediators, inducing tolerance to the allergen by specific immunotherapy or even acting on factors related to activation and differentiation of T lymphocytes such as the toll-like receptors.

EXPERT OPINION

AC is an underestimated disease for which there is a search of more effective treatments. The availability of the drugs under current evaluation will allow more refined therapeutic strategies to apply according to the characteristics and the clinical severity of AC.